Preoperative Cessation of Both Dual Anti-Platelet Agents Is Safe after 1 Year in Patients Receiving Percutaneous Coronary Intervention.
Jeen Hwa LeeSang-Ho JoPublished in: Journal of lipid and atherosclerosis (2020)
Preoperative discontinuation of DAPT did not increase the risk of MACE. However, continuation of at least 1 antiplatelet agent increased the incidence of bleeding requiring RBC transfusion. Further research with a large cohort is warranted.
Keyphrases
- percutaneous coronary intervention
- antiplatelet therapy
- patients undergoing
- atrial fibrillation
- acute coronary syndrome
- st segment elevation myocardial infarction
- acute myocardial infarction
- coronary artery disease
- st elevation myocardial infarction
- cardiac surgery
- risk factors
- coronary artery bypass grafting
- sickle cell disease